Five hospitals in England and Wales have switched to urine test, rather than invasive hospital procedure ...
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...
Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer, offering a much-needed ...
Marks the first Medicare coverage decision for Veracyte’s whole-genome sequencing-based TrueMRD platform and launch of the first test Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics ...
Cellens, a Boston, MA-based cancer diagnostics startup, has raised a $6.5 million seed round. The company is developing a mechanobiology and AI-driven platform, BioFeel, for non-invasive cancer ...
Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results